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Abstract
Background: Meloxicam (MLX) is a nonsteroidal anti-inflammatory drug used in the relief of postoperative pain for
human and veterinary medicine. This study was designed to investigate the effect of surgery on the plasma
disposition of MLX in dogs undergoing ovariohysterectomy following a single intravenous injection at a dose of
0.2 mg/kg bodyweight. Eight crossbred bitches were used in the study. A two-phase experimental design with a
10-day washout period was used. Pre-operative MLX was administered intravenously to 8 bitches about 10 days
before surgery (Phase I, control) at a dose of 0.2 mg/kg bodyweight and peri-operative MLX was administered
intravenously after anaesthesia and 15 min before the start of surgery (Phase II). Blood samples were collected
from all animals at various times between 1 and 96 h after the drug administrations in both phases. The drug
concentrations were analysed using high performance liquid chromatography.
Results: The volume of plasma MLX distribution at steady-state (Vdss) of the control group (Vdss: 263.0 ml/kg)
was significantly greater (P < 0.05) compared to that of the surgery group (Vdss: 149.3 ml/kg). The AUC values
were higher (29.5 vs. 23.0 μg.h2/ml) and the CL values were lower (7.7 vs. 10.5 ml.h/kg) in the surgery group
compared to the control group, respectively, but differences were not significant.
Conclusions: The results of the present study indicated that surgery could alter the plasma disposition of MLX
and thus the drug efficacy and side effects such as gastrointestinal ulceration, unusual bleeding and loss of
kidney function/failure when repeated doses are used.
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Background
Analgesic drugs including nonsteroidal anti-inflammatory
drugs (NSAIDs), opioids and local anaesthetic agents are
used in dogs as peri- and post-surgery pain relievers.
NSAIDs are used in veterinary medicine for treating espe-
cially musculo-skeletal and abdominal pain [7]. These
drugs have antipyretic, anti-inflammatory and analgesic
properties. The common mechanism of action for this
class of drugs can be attributed to a blockade of the
biosynthesis of prostaglandins, resulting from the inhibi-
tionof enzyme cyclooxygenase (COX) [3, 21].
Meloxicam (MLX), belongs to the enolic acid class of
NSAIDs and is also effective as antipyretic, analgesic or
anti-inflammatory agent [20]. It preferentially inhibits
COX-2, which is induced by inflammatory stimuli in
pathophysiological conditions [9]. MLX is about 12
times more potent at inhibiting COX-2 than COX-1
activity [17].
Surgery is a duration when there are some major
stresses associated with pain, cardiovascular and possibly
major haemodynamic changes peri- and post-operation,
especially if there is a significant blood loss [1]. In general,
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the pharmacokinetics of drugs in most species have been
characterized in healthy animals. However, the plasma
disposition of the active compound and its metabolites
may be markedly altered in diseased animals or during
peri- or post-operative period.
The pharmacokinetics data are available for some
NSAIDs in dogs undergoing surgery and can be com-
pared with other published data [6, 7, 11, 27]. However,
to the best of our knowledge, this is the first study in
which the pharmacokinetic disposition of an NSAID in
dogs has been evaluated in the same animal with and
without surgery. Our hypothesis was that surgery alters
the plasma disposition of certain drugs including
analgesics and anaesthetics administered pre- or peri-
operatively. Therefore, this study was designed to investi-
gate the effects of surgery on the plasma disposition of
MLX in dogs undergoing ovariohysterectomy following a
single intravenous injection at 0.2 mg/kg bodyweight.
Results
Clinically no adverse effects were observed during and
after the MLX administration in dogs. The pre-operative
biochemical and haematological parameters were within
the normal ranges. Mean age, bodyweight, duration of
surgery and the selected surgical variables during anaes-
thesia are shown in Table 1. The heart rate, respiratory
rate and end tidal CO2 values were 122.17 ± 10.6 beats/
min, 8.5 ± 0.9 breaths/min and 42.06 ± 7.3 mmHg during
anaesthesia, respectively. The albumin levels of each dog
in the control group were similar to its own post-surgery
plasma albumin concentration. In addition, the mean al-
bumin concentration in the control group (2.43 ± 0.32 g/
dl) was not significantly different (P: 0.719) compared with
that observed in the surgery group (2.50 ± 0.23 g/dl).
The analysis yielded linear regression lines ranging
from 0.025 to 10 μg/ml of MLX with a correlation coef-
ficient of 0.999. The limits of detection and quantifica-
tion of the MLX assay were 0.005 μg/ml and 0.02 μg/ml,
respectively. The mean recovery was 98.32 % (inter assay
CV = 2.09 %) and the accuracy ranged from 96 % to
103 %.
Pharmacokinetic parameters of MLX following intra-
venous administration (0.2 mg/kg) are given in Table 2.
Semi logarithmic plot of the mean plasma concentration
vs. time curves are shown in Fig 1. In additions, the scat-
ter plots of the pharmacokinetic parameters (Vdss, T1/2,
Cl and AUC) in control vs. surgery group are presented
in Fig. 2.
The differences in most pharmacokinetic parameters
between the control and surgery groups were not sig-
nificant, however, variability was high for each phase.
Nevertheless, the terminal half-life (T1/2λz) and total
body clearance (ClB) values were longer and higher, but
the area under the curve (AUC) value was smaller in
the control group (T1/2λz: 17.21 h, ClB: 10.50 ml.h/kg
and AUC: 23.00 μg.h/ml) compared to the surgery
group (T1/2λz: 12.77 h, ClB: 7.70 ml.h/kg and AUC:
29.50 μg.h/ml), respectively. The volume of MLX distri-
bution at steady-state (Vdss) of the control group (Vdss:
263.00 ml/kg) was significantly larger (P < 0.05) com-
pared to that of the surgery group (Vdss: 149.30 ml/kg).
The Vdss value of each individual animal decreased in
phase I compared with that of the same animals in
phase II. Moreover, T1/2λz, AUC and MRT values in 7
out of 8 dogs were altered in the post-surgery group
compared to the control group.
Discussion
The plasma concentration of MLX in dogs following
intravenous administration exhibits slight fluctuations,
especially in the early hours of the administration in
both phases of the present study. Similar observations
were also reported by studies performed recently in
Table 1 Mean (±SD) values of general characteristics and
selected surgical variables during anaesthesia of eight dogs
undergoing ovariohysterectomy
Characteristic Mean ± SD
Operation time (min) 29 ± 7.9
Age (year) 1.4 ± 0.4
Bodyweight (kg) 18.25 ± 4.4
Time from MLX injection to start of surgery (min) 15 ± 0.0
Heart rate (per min) 122.17 ± 10.6
Respiration rate (per min) 8.5 ± 0.9
End tidal CO2 (mmHg) 42.06 ± 7.3
Oxyhaemoglobin (%) >98
Table 2 Median pharmacokinetic parameters with lower and
upper confidence intervals of meloxicam in control and surgery
groups following intravenous (0.2 mg/kg) administration to
bitches (n = 8)
Parameters Control group Surgery group P values
T1/2λz (h) 17.21 (12.8–40.1) 12.77 (9.8–24.3) 0.289
C0 (μg/ml) 1.05 (0.7–9.92) 5.3 (1.9–14.2) 0.298
AUClast (μg.h/ml) 21.2 (10.8–30.8) 28.5 (18.7–45.6) 0.176
AUC0→∞ (μg.h/ml) 23.0 (12.4–41.0) 29.5 (19.4–51.5) 0.322
AUMC0→∞ (μg.h2/ml) 698 (378–2815) 588 (329–2150) 0.959
ClB (ml.h/kg) 10.5 (6.0–20.6) 7.7 (4.9–11.35) 0.191
Vdss (ml/kg) 263.0 (211–470) 149.3 (122.4–172.7) 0.016*
MRT0→∞ (h) 28.1 (19.5–56.0) 20.7 (14.4–34.3) 0.303
C0: plasma concentration at time 0, AUC0→∞: area under the (zero moment)
curve from time 0 to infinity, T1/2λz: terminal half-life, AUMC0→∞: area under
the moment curve from time 0 to infinity; ClB: total body clearance of drug;
Vdss: volume of distribution at steady-state; MRT0→∞: mean residence time
*The kinetic parameters in control group are significantly different (P < 0.05)
from the surgery group
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dogs, cats and horses subjected to ketorolac treatment
[7, 11, 27]. The reason of such characteristics in plasma
concentrations is not clear and probably not associated
with the anaesthetic agents and surgical procedures
employed in the experiments, since similar fluctuations
were observed in the animals of the control group.
There is a reasonable body of literature evaluating peri-
or post-operative analgesic effects and plasma dispositions
of some NSAIDs in dogs undergoing surgery [4, 7, 8, 12,
24]. However, to our knowledge this is the first study in
which the pharmacokinetics of an NSAID in dogs have
been evaluated in the same animal with and without sur-
gery. Although, all animals under surgery receive at
least 1 drug during the operation for pre-anesthetic
medication, anesthesia or analgesia in the surgery unit,
there is no information available on the alterations in
drug disposition following surgery in veterinary medi-
cine. During the surgery, many hemodynamic and
metabolic alterations such as fluctuating hemodynamics,
alteration of protein catabolism and anabolism may occur.



























Fig 1 Semi log plot of mean (±SD) plasma concentrations vs. time
curves of meloxicam in control and surgery groups following
intravenous (0.2 mg/kg) administration to bitches (n = 8)







































































Fig 2 The scatter plots of some pharmacokinetic parameters (Vdss, T1/2, Cl and AUC) in control group vs. surgery group following intravenous
(0.2 mg/kg) administration of meloxicam to dogs (n = 8)
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The changes in circulation, blood volume, extracellular
fluid and blood protein levels, such as α1-acid glycopro-
tein and albumin may affect the distribution of drugs used
during the peri- and post-operative periods [18].
The kinetic parameters of MLX observed from the
control group in the present study exhibits a low appar-
ent volume of distribution (263.00 ml/kg) and a long
plasma half-life (17.21 h) and residence time (28.10 h) in
dogs following the intravenous administration. These
findings are in agreement with the results of a previous
study [5], regarding the values of Vss (320 ml/kg), T1/2
(24.0 h), MRT (34.8 h) and AUC (21.5 μg.h/kg) in
healthy dogs.
The differences in most pharmacokinetic parameters be-
tween the control and surgery groups were not significant,
however, variability was high for each phase. The dogs in
the control group were demonstrated to have a prolonged
half-life (17.21 h vs 12.77 h), smaller AUC (23.00 μg.h/ml
vs 29.50 μg.h/ml) and greater body clearance (ClB)
(10.50 ml.h/kg vs 7.70 ml.h/kg) when compared to them-
selves in the surgery group. Moreover, the volume of
MLX distribution at steady-state in the control group
(Vdss: 263.00 ml/kg) was significantly greater than that of
the surgery group (Vdss: 149.30 ml/kg). Volume of distri-
bution (Vdss) is one of the most important parameters for
the evaluation of the pharmacokinetic characteristics of
the drugs and depends on many factors, including the
physicochemical properties of the drug, binding strength
of plasma proteins, binding capacity to the other tissues.
The reason for low levels of Vdss measured in surgery
group is probably associated with major haemodynamic
changes during the surgery and/or drug-drug interaction.
The hepatic activity increases during the post-operative
period. Serum albumin turnover elevates, drug-albumin
binding characteristics alter and the level of serum pro-
teins, including albumin decreases dramatically for a
period following surgery [18]. In addition, it has been re-
ported that the serum albumin level was significantly re-
duced in dogs with inflammation compared with the
healthy dogs [2]. Besides, high plasma albumin binding of
MLX could be altered by the anaesthetic drugs, since it
has been reported that the plasma proteins (albumin,
globulin) decreases in under isoflurane anaesthesia in fly-
ing fox [15]. Both the duration and the intensity of drug
action with the free drug concentration being the active
compound are affected by the level of protein binding
[26]. In these circumstances, the protein binding is influ-
enced, particularly for the drugs which have more than
90 % protein bound [18]. The protein binding ratio of
MLX in dogs was reported as 97 % [5] and MLX exhibits
a high degree of binding to albumin [16]. Generally, the
reduction of plasma protein leads the increase of distri-
bution volume and clearance of drugs via the decrease
in the plasma protein bindings. However, the mean
albumin concentration in the control group (2.46 g/dl)
was not significantly different (P: 0.719) compared with
that observed in the surgery group (2.48 g/dl) in the
present study. Consequently, the difference on Vdss of
MLX is probably not related to the different plasma al-
bumin level between the control and surgery groups.
The reason for lower Vdss in the surgery group was
however unclear. It is probably related to the other fac-
tors such as drug-drug interaction which may have
changed the drug-protein binding capacity in the sur-
gery group since atropine sulphate, propofol and iso-
flurane were combinely used for premedication and as
anaesthesia. Also ovariohysterectomy may have affected
reproductive hormones and thus the disposition of the
drugs. In addition, the reason for lower Vdss in the sur-
gery group could be, at least in part, due to smaller ClB
and MRT as Vdss = ClB ×MRT. Moreover, there was a
limitation since the control and surgery phases (I and
II) were arranged in a sequence, but not in a crossover
fashion. This experimental design may potentially in-
duce a period effect. However, this is judged to be un-
likely as a 10-day washout period was considered to be
sufficiently long [22].
In the present study, the effect of surgical operation
on the plasma disposition of MLX was investigated in
only crossbred and female dogs. However, the plasma
disposition of MLX may be different in pure-bred and
between male and female dogs. The elimination half-
life of naproxen in beagles (T1/2: 35 h) was much
shorter [25], compared with that of observed in mon-
grels (T1/2: 74 h) [13]. This difference probably reflects
a breed difference, since it is known that beagles me-
tabolise drugs more rapidly than other breeds [14]. Be-
sides, it has been reported that, female dogs showed
lower AUC and elimination T1/2 values of MLX, com-
pared with male dogs [5].
Conclusions
Vdss of MLX in the control group is significantly
greater compared to that of the surgery group. Gener-
ally limited or lowered distribution may decrease the
drug exposure into tissues. However, the consequent
reduction in volume of distribution leads to higher
plasma concentrations of MLX. Besides, higher plasma
concentration of the increased unbound MLX fraction
in plasma may increase risk of side effects such as
gastrointestinal ulceration, unusual bleeding and loss of
kidney function/failure when repeated doses are used.
The change in the disposition of some drugs pre-, peri-
and post-operatively administered for pre-medication,
anaesthesia or prevention of post-operative infections
may result in changing efficacy and/or increasing side
effects or toxicity.
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Methods
Experimental animals
A total of 8 client-owned, cross-bred bitches, 2–4 years
old and weighing 18.25 ± 4.4 kg were used in the study.
Animals were judged to be healthy on the basis of phys-
ical examinations and haematological and biochemical
blood tests. All animals were housed in single boxes and
each dog was identified by natural markings. Water was
supplied ad libitum and animals were fed a standard
commercial diet twice daily with an appropriate quantity
of feed during the experimental period. The animals
were acclimated for 5 days before the study and food
was withdrawn 12 h before the drug administrations in
pre- and peri- surgery.
The study was designed as a two-phase trial with a 10-
day washout period as this time duration was reported
to be adequate for ensuring the clearance of the drug in
dogs [22]. A bolus of MLX was administered intraven-
ously to each dog about 10 days before the surgery
(Phase I, control) at a dose of 0.2 mg/kg bodyweight and
peri-operative MLX was administered intravenously after
the anaesthesia and 15 min before the start of the sur-
gery (ovariohysterectomy) (Phase II) at the same dose
0.2 mg/kg bodyweight. MLX administration and blood
sampling were performed through the different cephalic
veins of each dog. All animals were enrolled after written
consent of the owners. The experimenters were blinded
to the pharmacological treatment, while processing data
and making exclusion decisions. All procedures were
carried out under a protocol approved by the Animal
Ethics Committee of Adnan Menderes University (Refer-
ence number: 64583101/2014/170). All sections of this
paper adheres to the ARRIVE Guidelines for reporting
animal research [19].
Pre-surgical and surgical procedures
All dogs in phase II were administered to the following
anaesthetic protocol: premedication by subcutaneous atro-
pine sulphate (0.045 mg/kg bwt, Teknovet Atropine;
Teknovet, Turkey), induction by intravenous bolus of pro-
pofol (4 mg/kg bwt, Propofol 1 %; Fresenius, Fresenius
Kabi) administered for inducing the anaesthesia. After in-
tubation, the anaesthesia was maintained with isoflurane
(Isoflurane USP; Adeka, Turkey). Different levels of
isoflurane were used during anaesthesia, to maintain an
appropriate depth of anaesthesia based on clinical assess-
ment; heart rate (HR), invasive blood pressure (IBP),
muscle relaxation, the degree of nystagmus and response
to the surgery were monitored.
MLX (Bavet Meloxicam; Bavet, Istanbul-Turkey) was
administered intravenously as a bolus at a dose of 0.2 mg/
kg bodyweight after intubation and 15 min before the start
of the surgery.
After the dog was anesthetized, a standard aseptic
preparation was performed, which was followed by
elective ovariohysterectomy via a routine ventral mid-
line approach. Same surgeon performed all ovariohys-
terectomy operations. Respiration rate, HR, IBP, EtCO2,
oxyhaemoglobin saturation, electrocardiography (lead
II), and body temperature were recorded every 5 min
during the operation period using an Utech monitor
(VS2000V Vital Signs Monitor; Utech Co. Ltd., China).
Sample collection
Heparinized blood samples (3 ml) were collected by
cephalic venepuncture using a 20 G catheter (B&D
Medical Systems; Istanbul, Turkey) prior to drug admin-
istration (0 h), 5, 15, 30, 45 min and 1, 2, 4, 6, 8, 10, 12,
16, 24, 32, 40, 48, 72 and 96 h after the administration
of MLX. Blood samples were centrifuged at 3000 g for
20 min and plasma was transferred to plastic tubes
(5 ml). Heparinized drug-free blood samples for analyt-
ical method development and validation process were
collected from other dogs not included in the study. All
the plasma samples were stored at −20 °C until the esti-
mations of drug concentrations.
Analytical procedures
The parent compounds of MLX in dog plasma were
analysed using validated high performance liquid chro-
matography (HPLC) following a liquid-liquid phase ex-
traction procedure. Plasma concentrations of MLX
were measured by minor modifications of the methods
described by Eniko et al. [10].
Stock solution (100 μg/ml) of pure standard of MLX
(Dr. Reddy’s Laboratory, India) was first prepared using
acetonitrile: water (20:80) as solvent. The resulting stock
was then further diluted to produce 0.05, 0.5, 1, 2.5, 5
and 10 μg/ml solutions for calibration as standard curves
and to add to the drug-free plasma samples to determine
the recovery.
The mobile phase consisted of acetonitrile : 1 % aqueous
glacial acetic acid (40:60, v/v) and was delivered (Agilent
1260 Series binary pump; Waldron, Germany) at a flow
rate of 1.2 ml/min. An analytical column (Zorbax CN,
5 μm, 4.6 mm x 250 mm; Agilent Technologies, Wilming-
ton, DE) was used for the analysis of MLX. The eluate was
continuously monitored using a photodiode array detector
(Agilent 1260 Series Technologies; Waldron, Germany) at
a wavelength of 360 nm.
The method for MLX analysis in plasma was validated
before the start of the analysis of the study samples. The
chromatographic peak of MLX was identified with the re-
tention times of its analytical standard. Recovery of the
molecule was determined by comparison of the peak areas
from the spiked plasma samples with the areas resulting
from direct injections of the analytical reference standard.
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The inter- and intra-assay precisions of the extraction and
chromatography procedures were evaluated by processing
replicate aliquots of drug-free dog plasma samples con-
taining known amounts of the drug on different days.
Calibration graphs were prepared (linear range 0.025-
10 μg/ml). The slope of the lines between peak areas and
drug concentration was determined by least squares linear
regression and showed a correlation coefficient between
0.9987 and 0.9999. The detection limit of the molecule
was established with HPLC analysis of blank plasma
spiked with the analytical standard and measuring the
baseline noise at the peak retention time. The limit of
detection (LOD) and limit of quantification (LOQ) were
determined for the HPLC method. The limits were deter-
mined based on the standard deviation amongst response
and slope of the curve at the lowest concentrations.
Plasma albumin concentrations of all samples of each
animal were determined by autoanalyser (Sinnowa D280,
China), using bromocresol green (Archem A2011, İstanbul,
Turkey) as described by Lolekha and Charoenpol [23].
Pharmacokinetics and statistical analysis of data
The plasma concentration vs. time curve obtained after
the treatment was fitted with the WinNonlin software
program (version 5.2, Pharsight Corp., Mountain View,
California, US). The pharmacokinetics parameters for
each animal were estimated using non-compartmental
model analysis. The trapezoidal rule was used to calcu-
late the area under the plasma concentration time
curve (AUC).
The pharmacokinetic parameters are reported as
median with lower and upper confidence intervals. The
characteristics of dogs (Table 1), the plasma albumin
concentrations (Table 2) and the plasma concentrations
vs. time curves of MLX (Fig. 1) were expressed as mean ±
SD. The pharmacokinetic parameters and plasma albumin
concentrations were statistically compared with a Wilcox-
on’s signed rank test a nonparametric approach for paired
data. All statistical analyses were performed by using
MINITAB for Windows (release 12.1, Minitab Inc., State
College, PA, USA). Mean values were considered signifi-
cantly different at P < 0.05.
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